Hepatitis B and C Immunological and Molecular Parameter Analysis in HIV-Positive Patients Undergoing Antiretroviral Therapy at Saint Camille Hospital in Ouagadougou (HOSCO), Burkina Faso

Knowledge of the clinical and biological profile patients infected with HIV hepatitis B and/or C is essential in order to identify implement effective management strategies. Methods: This was a retrospective descriptive study from January 01, 2016 June 2021. Adult aged at least 18 years type 1 2, na?ve ARV treatment. Univariate analyses were assessed using Pearson’s Chi2 test. The Student Newman test used for comparison between groups R software version 4.0.2. Objective: To draw up epidemiological, clinical, paraclinical evolutionary profiles HIV-treated-patients relation HIV/HBV HIV/HCV co-infections allow identification implementation Results: Of 379 included 280 (73.88%) women. At treatment initiation, mean age 40.14 ± 11.84 years. majority consulted WHO stage III (51.45%). Clinical suspicion most frequent screening circumstance (51.71%). pathologies frequently reported first consultation diarrhea (28%) shingles (16%). Body mass index normal 50.5% patients. HIV1 infection (91.03%). A total 270 had CD4 count initiation. cell 304.17 242.06 cells/μL, 116 (42.59%) them ≤ 200 cells/μL. Viral load initiation documented 62 (16.35%) 70.97% detectable viral (greater than 1000 copies/mL). evolution relatively good after therapeutic HIV-HBV co-infection 24.11% HIV-HCV 2.26%. mortality rate 3.69%. Conclusion: These results reflect significant delay diagnosis. Furthermore, that increasingly affect people living HIV. It also appears COVID 19 disease has strong impact on patient management. Thus, new strategies must be implemented encourage early diagnosis HIV, C. Effective are necessary fight context epidemics pandemics.